Clinical Trial: A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title:
Brief Summary: This study is a retrospective chart review to evaluate the doses of botulinum Type A toxins BOTOX® (onabotulinumtoxinA) and Xeomin® (incobotulinumtoxinA) used for the treatment of Cervical Dystonia and Blepharospasm in clinical practice.
Detailed Summary:
Sponsor: Allergan
Current Primary Outcome:
- Dose of Botulinum Toxin Used to Treat Cervical Dystonia [ Time Frame: 4 Years ]
- Dose of Botulinum Toxin Used to Treat Blepharospasm [ Time Frame: 4 Years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Botulinum Toxin Inter-injection Intervals [ Time Frame: 4 Years ]
- Number of Participants with Adverse Events [ Time Frame: 4 Years ]
- Annual Botulinum Toxin Dose per Patient [ Time Frame: 4 Years ]
Original Secondary Outcome: Same as current
Information By: Allergan
Dates:
Date Received: September 18, 2014
Date Started: August 2015
Date Completion:
Last Updated: January 6, 2016
Last Verified: January 2016